Azitra is trading 7.8% down at $0.12 as investors remain focused on its NYSE American non-compliance status and potential delisting risk.
- Ongoing concerns regarding low share price levels persist, which could trigger a trading suspension or necessitate a reverse stock split to maintain listing requirements.
- Sentiment is further dampened by continued profit-taking pressure across the broader biotechnology sector, extending the stock's recent downtrend.